Diketopiperazines

• 

  Subject Areas on Research

  • Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals. 
  • HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry. 
  • HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells. 
  • In vitro and clinical investigation of the relationship between CCR5 receptor occupancy and anti-HIV activity of Aplaviroc. 
  • PIP5K1α inhibition as a therapeutic strategy for prostate cancer. 
  • Probing conformational changes in human DNA topoisomerase IIα by pulsed alkylation mass spectrometry. 
  • Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism. 
  • Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir-ritonavir: detection of aplaviroc resistance requires clonal analysis of envelope.